765 results on '"Seike, Masahiro"'
Search Results
2. Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention—prospective, single-center, randomized, parallel-group study
3. Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy
4. Influence of background cardiovascular risk factors on VEGF inhibitor-related adverse vascular events in patients with non-small cell lung cancer: a retrospective study
5. Lower optimal dose of amrubicin for relapsed small-cell lung cancer: a retrospective study
6. Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
7. Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer
8. Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060
9. Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients
10. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)
11. A highly specific antibody against the core fucose of the N-glycan in IgG identifies the pulmonary diseases and its regulation by CCL2
12. Minimal effective dose of maintenance steroid therapy for relapse of cryptogenic organizing pneumonia
13. Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
14. Increased CTGF expression in alveolar epithelial cells by cyclic mechanical stretch: Its mechanism and the therapeutic effect of pirfenidone
15. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study
16. Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)
17. DOCK2 is involved in the host genetics and biology of severe COVID-19
18. Interstitial lung disease with prolonged fever that occurred during long-term administration of olaparib in a 74-year-old ovarian cancer patient: Radiological features and considerations for preventing delayed diagnosis
19. Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients
20. Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer
21. Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis
22. Compatible with fibrotic hypersensitivity pneumonitis on high-resolution computed tomography: from the ATS/JRS/ALAT 2020 hypersensitivity pneumonitis guidelines
23. Two cases of superior mesenteric artery syndrome during chemotherapy in patients with lung cancer
24. Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
25. Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042)
26. Clinicopathological characteristics of kidney injury in non-small cell lung cancer patients under combination therapy including pembrolizumab
27. The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force
28. Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study
29. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
30. Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR‐mutated NSCLC with high thrombospondin‐1 expression.
31. Treatment patterns and clinical outcomes of resectable clinical stage III non‐small cell lung cancer in a Japanese real‐world setting: Surgery cohort analysis of the SOLUTION study.
32. Smoking-Related Interstitial Fibrosis and Smoker's Macrophages
33. Clinical significance of PD-1-binding soluble PD-L1 and MMPs in the microenvironment of gastric cancer and non-small cell lung cancer treated with PD-1/PD-L1 blockade
34. Improvement in idiopathic interstitial pneumonia by adding macitentan to a patient unresponsive to nintedanib
35. Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations
36. Pharmacological blockage of transforming growth factor-β signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846
37. Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.
38. Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients
39. MO1-2 Subgroup analysis of atezo + bev + carbo + pac for previously treated patients with EGFRm NSCLC (NEJ043)
40. MO1-4 Efficacy of immune checkpoint inhibitors plus chemotherapy for TTF-1-negative non-squamous non-small cell lung cancer
41. EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells
42. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
43. Acinetobacter baumannii can be transferred from contaminated nitrile examination gloves to polypropylene plastic surfaces
44. Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study
45. Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
46. Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer
47. Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention— prospective, single-center, randomized, parallel-group study
48. Pulmonary manifestation of inflammatory bowel disease: Two case reports
49. Development of eosinophilic pneumonia from eosinophilic bronchiolitis without asthma: A case report
50. Mechanism of Resistance to Targeted Molecular Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.